Maze Therapeutics

Phase A — Understand the business

Company Overview

Maze is a clinical-stage biopharmaceutical company using human genetics to design oral small-molecule precision medicines for kidney and metabolic disease. The model is the inverse of "drug a target and hope" — Maze starts from naturally occurring protective genetic variants in large human-genetics cohorts (Million Veteran Program, Vanderbilt BioVU, NIH All of Us), functionalizes them on a platform called Compass, and then designs molecules to phenocopy the protective variant. The thesis: a target validated by human genetics carries a higher probability of clinical success than one validated only in mice.

Two wholly-owned clinical assets are the company today:

• MZE829 — oral APOL1 inhibitor for APOL1-mediated kidney disease (AMKD). Phase 2 (HORIZON) proof-of-concept reported March 2026. The crown jewel.
• MZE782 — oral SLC6A19 inhibitor for phenylketonuria (PKU) and chronic kidney disease (CKD). Phase 2-ready; two Phase 2 starts planned in 2026.

The business has a second engine that is unusual for a pre-revenue biotech: it is a serial out-licensor. Compass has spun out at least four partnered programs, converting platform output into non-dilutive cash:

• MZE001 (Pompe disease) → licensed to Shionogi (March 2024), $150M upfront + milestones + tiered royalties. Now in Shionogi-run Phase 2; Maze collected a $20M clinical milestone in April 2026 on first-patient-dosed.
• ATXN2 (ALS) → licensed to Neurocrine Biosciences (May 2024), upfront + milestones + royalties.
• UNC13A (ALS) → licensed to Trace Neuroscience, upfront + milestones + royalties.
• ANGPTL7 (glaucoma) → a ~50% equity JV with Alloy Therapeutics.

Customers/payers: none yet — no product revenue, ever. The "customers" of the platform are its pharma partners (Shionogi, Neurocrine). End customers for the wholly-owned assets would be nephrologists and (for PKU) metabolic specialists, with payer reimbursement the eventual gate. Suppliers: CROs for trials and CMOs for manufacturing — Maze runs an asset-light, outsourced clinical model (no owned manufacturing). Contract structure: the partnered deals are the only "revenue" mechanics — upfront + development/regulatory/commercial milestones + tiered royalties; Maze surrenders control (Shionogi controls MZE001 prosecution and development decisions) in exchange for capital and validation.

Incorporated in Delaware; HQ South San Francisco; IPO'd on Nasdaq February 2025 (ticker MAZE). Emerging-growth company and smaller-reporting-company status (reduced disclosure, no auditor ICFR attestation yet).

Supply Chain → CDMO / data-supply map

For a platform biotech the "supply chain" has two distinct spines:

1. The data spine (the actual moat input). Compass is only as good as the genetic data it ingests. Maze depends on access to high-quality paired genetic-and-clinical data repositories — named in the filing: the Million Veteran Program (~121,000 African-ancestry participants used to validate the N264K protective variant for APOL1), Vanderbilt University Medical Center BioVU, and the NIH All of Us program. This is a flagged single-point dependency: the 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. lists "loss of access to high-quality data repositories" as a principal risk that "could have a material adverse effect". These are third-party / government datasets Maze does not own.

2. The molecule spine (outsourced).

• Inputs: small-molecule APIs and drug substance — sourced via third-party CMOs (the filing flags reliance on "CROs, CMOs, suppliers and manufacturers").
• Maze: discovery + clinical development + (eventually) targeted US commercialization for the wholly-owned assets.
• Clinical execution: CROs run the trials.
• End channel: for MZE829/MZE782, Maze intends to commercialize independently in geographies where it can build "targeted capabilities"; for the out-licensed assets, the partner (Shionogi, Neurocrine, Trace) carries manufacturing, trials, and commercialization.

Chokepoints: (1) data-repository access (named, single-source-ish, government-dependent); (2) CMO concentration for clinical supply (standard small-pharma risk, not yet quantified); (3) for the partnered programs, total dependence on partner effort and prioritization — Maze has "significant" exposure to partners deprioritizing programs.

Competitive Advantages (moats) → platform / IP / data moat

The moat claim is the Compass platform plus its genetics dataset access plus the IP estate. How real is each?

• Platform / process moat (genuine but unproven at scale): Compass's "variant functionalization" — identifying a protective variant (e.g. APOL1 N264K, associated with a 57% reduced CKD risk and 81% reduced ESKD risk in high-risk carriers in a meta-analysis) and designing a molecule to mimic it — is a differentiated discovery engine. The proof that it works is external validation: four pharma/biotech partners have paid for Compass output (Shionogi, Neurocrine, Trace, Alloy), and the lead internal asset just cleared clinical PoC. That is meaningful third-party validation of the platform — rare for a 2019-vintage biotech.
• IP moat: composition-of-matter and method patents across programs; the GYS1/MZE001 portfolio (licensed to Shionogi) projects to ~2042–2043. For the wholly-owned APOL1 and SLC6A19 assets, patent life is the durable exclusivity once approved. The 10-K flags the standard biotech IP fragility (cost, scope, infringement).
• Data-access moat (the weakest link): access to MVP/BioVU/All of Us is not exclusive to Maze — these are broadly available research datasets. The advantage is in the functionalization methodology, not proprietary data ownership. A well-funded competitor (Vertex, Regeneron's genetics center, AstraZeneca's Centre for Genomics Research) can mine the same cohorts.

Bargaining power: as a sub-$1.5B pre-revenue biotech, Maze has limited bargaining power over large pharma partners (Shionogi/Neurocrine dictate development of the licensed assets) and over future payers. Its leverage is the scarcity of genetically-validated kidney targets — which is why partners came to the table. Net: a real-but-narrow moat — the platform is validated by deals and one clinical readout, but the data inputs are not proprietary and the lead indication is contested by a far larger rival (Lens 13).

Segments

Maze reports as a single operating segment (clinical-stage R&D); there is no product-segment or geographic revenue breakout because there is no product revenue. The only "revenue" the company has ever recognized is license revenue, which is lumpy and deal-driven, not recurring:

*The Q1 2026 net-loss narrowing (below) is driven by lower convertible-note fair-value swings and timing, not in-quarter product/license revenue; the $20M milestone is a Q2 2026 event.

The "segment" trend that matters: the only recurring economics are the milestone/royalty streams owed by partners — and those resolve on the partners' clinical timelines, not Maze's. The company is structurally a development-stage entity with episodic non-dilutive cash injections. Do not model a revenue ramp here; model cash burn vs. catalyst (Lens 11).

---

Phase B — Measure performance (clinical-variant: pipeline-by-phase, not earnings)

Pipeline by phase

The asset table is the company.

The MZE829 HORIZON Phase 2 readout (March 25, 2026) — the single most important data point in this dossier:

• Open-label, 12-week basket trial; 15 enrolled (safety), 12 evaluable (efficacy).
• Broad AMKD: mean uACR (proteinuria) reduction 35.6% at week 12; 50% of evaluable patients hit ≥30% reduction.
• FSGS subset: 61.8% mean uACR reduction.
• Non-diabetic AMKD: 48.6% mean reduction.
• Safety: clean — no serious AEs, no severe treatment-related AEs; most common TRAEs headache and diarrhea (2 patients each); one discontinuation for mild nausea.
• Phase 1 (n=111 healthy volunteers, reported Oct 2024): well tolerated to 350 mg/day; ~15-hr half-life supports once-daily; no clinically significant drug-drug interactions with standard-of-care immunosuppressants.

This is the first clinical proof-of-concept for an oral APOL1 inhibitor in a broad AMKD population (vs. the narrower FSGS-led framing). The catch: N=12 evaluable, open-label, no placebo arm. The efficacy signal is real and the safety is clean, but the statistical heft is thin — which is exactly what the tape reacted to (Lens 8).

MZE782 mechanism color: dose-dependent increases in 24-hr urinary excretion of phenylalanine and glutamine confirmed SLC6A19 target engagementTarget engagementA measurement showing the drug actually reached and acted on the thing in the body it was aimed at.; and dose-dependent eGFR changes similar to SGLT2 inhibitors hint at a CKD benefit — giving the asset a two-indication shot (rare-disease PKU + large-market CKD).

Management focus / call sentiment (founder-platform framing)

No earnings-call transcripts on the research-layer shelf (transcripts=0); sentiment is read from the IR/press cadence. What management is focused on, in order of emphasis: (1) converting the MZE829 HORIZON PoC into a pivotal program in AMKD; (2) launching two MZE782 Phase 2 trials in 2026 (PKU mid-year, CKD H2); (3) reinforcing the balance sheet — they raised in the Sept-2025 private placement and the April-2026 follow-on, explicitly to fund into 2029; (4) milestone harvesting from the partnered book (the $20M Shionogi event was foregrounded). Tone in 2026 communications is confident-but-defensive — every readout headline leads with "first clinical proof-of-concept" and "broad AMKD," language clearly chosen to differentiate from Vertex's FSGS-anchored positioning. The recurring phrase is "genetically validated"; the thing they must keep saying is that broad AMKD (diabetic + hypertensive, not just FSGS) is the real prize.

Catalyst calendar + mechanism comps

Catalyst calendar (the only valuation clock that matters for a pre-revenue name):

Mechanism comps (by target, not by P/E — this is a clinical-stage name):

• APOL1 / AMKD (MZE829's arena): the dominant comparator is Vertex Pharmaceuticals' inaxaplin (VX-147) — same target (APOL1 inhibition), same oral once-daily framing (45 mg), Breakthrough Therapy Designation, and two years ahead in Phase 3 (AMPLITUDE: full enrollment H2 2026, interim early 2027, accelerated-approval filing on a positive interim). There is no approved AMKD therapy today — so the race is for first/best, and Vertex is first. Maze's pitch is broad AMKD (diabetic + hypertensive) vs. Vertex's FSGS-anchored lead, plus a possible dual-mechanism differentiation.
• PKU (MZE782): competes against BioMarin's Palynziq/Kuvan franchise and PTC's sepiapterin — but as an oral SLC6A19 mechanism it is differentiated from enzyme-replacement.
• Pompe (MZE001, partnered): Sanofi (Nexviazyme) and Amicus (Pombiliti+Opfolda) own the enzyme-replacement market; MZE001 is a substrate-reduction oral — Shionogi's problem now.

Stock-Price Catalysts (what actually moves MAZE)

MAZE has only traded since February 2025, so the "5-year" history is ~16 months — but the pattern is already legible and brutal:

• IPO (Feb 3, 2025): priced at $16.00/share, $140M gross. As of June 30, 2025 the stock was $12.27 (below IPO) — a soft first half.
• March 25, 2026 — HORIZON Phase 2 positive data → stock −35.24% on the day. This is the defining tape event. Positive, clean data — and a one-third haircut. The market's read: the broad-AMKD effect (35.6%) wasn't the blowout bulls wanted, N was tiny, and the Vertex shadow means even a good Maze drug may arrive second into a market Vertex defines. "Buy the rumor, sell the (good-but-not-great) news," amplified by competitive overhang.
• April 2026 — follow-on at $23.50/share. Notably, the stock had recovered well above the post-data low to support a $23.50 raise within weeks — so the −35% day was partly a violent de-risking of over-positioned holders, not a permanent verdict. Sell-side then raised targets (JPM $58, Leerink $50, PoS 65%).

What the tape tells you MAZE reacts to: (1) MZE829 clinical data above all; (2) the Vertex competitive readouts (AMPLITUDE will move MAZE as much as Maze's own news); (3) financings (dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company. events, but also balance-sheet de-risking). Macro/rate sensitivity is high (unprofitable small-cap biotech), but idiosyncratic catalysts dominate.

---

Phase C — Judge people & books (+ science & exclusivity)

Management

• Track record: CEO Jason Coloma, Ph.D., M.P.H., MBA — former venture partner at Third Rock Ventures (Maze's founding investor) and Maze's prior COO; before that, VP & global therapeutic-area head of oncology and cancer-immunotherapy partnering at Roche, plus L.E.K. Consulting and Amgen finance. A business-and-dealmaking operator, not a bench scientist — which fits a company whose distinctive competence so far is out-licensing platform output (four deals). Chair: Charles Homcy, M.D. (former interim CEO), a seasoned biotech executive.
• Founders (the science pedigree is elite): Aaron Gitler, Jonathan Weissman, Mark Daly, Sekar Kathiresan, Stephen Elledge — a who's-who of human genetics (Daly = statistical genetics/Broad; Kathiresan = cardiovascular genetics, later Verve; Elledge = DNA-damage; Weissman = functional genomics). This is genuine founder-class scientific firepower, even if day-to-day is run by a professional manager.
• Tenure & skin in the game: Maze launched 2019 (Third Rock/ARCH) with $191M; raised ~$496M total private + the IPO. Insider-transactions CSV is empty on the shelf, so insider holdings are not quantified here — n/a for precise insider %. Note the 10-K cover excludes a "10%-or-greater holder" from the non-affiliate float, implying at least one large insider/VC block remains.
• Capital allocation: for a pre-revenue name this is financing + program prioritization, and here the record is good: monetized non-core platform assets for $150M+ non-dilutive (Shionogi/Neurocrine/Trace), raised opportunistically into strength (Sept-2025 PP and April-2026 follow-on at a premium to the prior price), and added a $200M Hercules debt facility for flexibility. Funding into 2029 with the lead asset in pivotal is disciplined runwayRunwayHow long the cash lasts at the current rate of spending. It shortens the moment spending rises, which is why a figure taken from a quiet quarter flatters. management.
• Red flags (minor, worth watching): the CEO's 10b5-1 trading plan churn — adopted Oct 2025 (up to 103,504 shares), terminated Feb 5, 2026 with zero shares sold, then re-adopted the same day at 4× size (up to 414,012 shares) running May 2026–May 2027. Terminating-then-quadrupling a sell plan ~7 weeks before a major data readout is legal and the original plan sold nothing, but the direction (a much larger pre-arranged sell window opening right after the catalyst) is a sentiment yellow flag, not a governance red one.
• Archetype: founder-science + professional-manager CEO. Implication: strong target-discovery and dealmaking; the open question is clinical-development and (eventually) commercial-build execution, which this team has not yet proven on a wholly-owned launch.

Forensic Red Flags

For a clinical-stage company the forensic surface is small (no revenue to manipulate, no inventory/receivables games) but real:

• Revenue recognition: the only revenue is license revenue, and it is violently lumpy — $167.5M (2024) → $0 (2025). A naive screen would see "2024 net income $52.2M" and call Maze profitable. It is not. The 2024 "profit" is an artifact of recognizing the Shionogi $150M upfront + Trace upfront in one year; strip the one-time license revenue and the company burns ~$130M+/yr. This is the single most important forensic point: do not annualize 2024..
• Convertible-note fair-value swings: pre-IPO convertible promissory notes ran through the P&L as fair-value changes (e.g. a $8.8M fair-value loss in 2024; small derivative on the old loan's IPO success fee). These are now resolved (notes converted at IPO; old loan terminated Feb 2026) but explain prior-period noise.
• Cash vs. earnings divergence: there is no positive earnings to reconcile — net cash used in operating activities tracks the ~$130M loss adjusted for ~$21.5M non-cash (SBC, D&A). Net cash provided by financing was $275.3M in 2025 (IPO $127.8M net + PP $141.3M net + option exercises) — i.e. the company runs on financing, as expected pre-revenue.
• SBC flatter: stock-based comp is a real non-cash expense embedded in the R&D/G&A growth (R&D $108.4M, G&A $34.5M in 2025) — watch dilution, not non-GAAP adjustments (Maze doesn't lean on non-GAAP).
• Going concern: no going-concern qualification — the company states cash is sufficient for "at least one year," and with the April raise, runway extends into 2029. Healthy for a clinical name.
• Internal controls: management concluded ICFR was effective as of 12/31/2025; no auditor ICFR attestation (EGC/non-accelerated-filer exemption) — standard for a recent IPO, but the audit assurance is one notch lower than a mature filer.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER) for 2021-06-22 → 2026-06-22 — total_sec_findings: 0.
• Item 3 Legal Proceedings (10-K, FY2025): "We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.". The 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. (Q1 2026) reaffirms: no material contingent liabilities accrued.
• Non-SEC enforcement (FTC/DOJ/FDA/etc.): web search returned no material enforcement actions, consent decrees, fines, or penalties naming Maze Therapeutics. (Appropriate for a company with no marketed product and no commercial conduct to police.)
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-22.

Science & exclusivity (clinical-variant addendum)

• Mechanism validation: APOL1 is one of the best human-genetics-validated targets in nephrology — the N264K protective-variant data (57% lower CKD, 81% lower ESKD risk, p<0.001, replicated across MVP/BioVU/All of Us) gives the target unusually high genetic confidence, and Vertex's competing Phase 3 + Breakthrough designation independently de-risk the biology. Target risk is low; molecule/clinical-execution risk is the live risk.
• KOL/founder credibility: founder roster (Daly, Kathiresan, Elledge, Weissman, Gitler) is top-tier human-genetics — high scientific credibility.
• IP / exclusivity: wholly-owned APOL1 (MZE829) and SLC6A19 (MZE782) composition-of-matter patents are the durable exclusivity; the licensed GYS1 estate runs ~2042–2043. No patent-cliff concern near-term (nothing approved yet).
• Payer/reimbursement path: AMKD has no approved drug, a clear genetic test to identify patients (high-risk APOL1 genotype), and severe outcomes (early ESKD, dialysis) — a favorable reimbursement setup for a disease-modifying oral, if the pivotal succeeds.

---

Phase D — Project & stress-test

rNPV + runway-to-catalyst (clinical-variant; no EPS line)

For a pre-revenue biotech, EPS three years out is meaningless (Maze will still be loss-making in FY2028). The two questions that matter:

(A) Does cash reach the next value-inflection catalyst? — YES, comfortably.

• Pro-forma cash (post April-2026 follow-on + $20M Shionogi milestone): ~$528M; reconciles to Q1'26 $362.9M + ~$144.7M net offering + $20M milestone.
• Plus a $200M Hercules facility ($40M drawn, up to $160M more in tranches; matures Feb 2031).
• Burn ~$130–150M/yr and rising as MZE829 enters pivotal and two MZE782 Phase 2s start. Company guides runway into 2029. That window spans: MZE782 Ph2 starts (2026), MZE829 pivotal start + interim, MZE782 PKU data (2027), and the Vertex AMPLITUDE interim (early 2027) — i.e. cash reaches multiple inflection points without a forced raise. Strong.

(B) Rough rNPV of MZE829 (lead asset) — illustrative, every input labeled ``:

• US addressable broad AMKD: ~250,000 patients (initial responsive population).
• Assume peak penetration 15–25% × ~$60–100k/yr net price (rare-genetic-CKD oral analog) → peak US sales ~$2.5–6B range.
• Probability of success: sell-side Leerink uses 65% post-Phase-2; a more conservative analyst PoS for a small open-label Ph2 with a pivotal still ahead would be 40–55%.
• rNPV (peak ~$4B × PoS ~0.50 × commercial-margin & discount haircut to ~25–30% of peak-sales-multiple) → rough enterprise value attributable to MZE829 alone of ~$1–2B+. Add MZE782 optionality (PKU + CKD), the partnered royalty stack (Shionogi/Neurocrine/Trace), and ~$528M net cash.
• Against a current market cap of ~$1.33B, the market is pricing MZE829 at a meaningfully sub-65%-PoS, Vertex-wins-most scenario. The gap between the $1.33B cap and the sell-side $50–64 consensus PT ($2.5–3.5B implied) is the entire trade..

Forecast log: in --watchlist (unattended) mode the SKILL says skip our model create. Not logging a Brier forecast here. (If promoted to a thesis, the scoreable binary would be: "MZE829 pivotal/registrational trial in AMKD meets its primary proteinuria endpoint," not an EPS line.)

Bull vs Bear

Bull case. Maze owns the #2 oral asset against the single best-genetics-validated target in nephrology, in a disease with zero approved drugs and ~250k US patients — and just printed clean, positive Phase 2 PoC across broad AMKD (not just FSGS), with a 61.8% effect in FSGS and 48.6% in non-diabetic AMKD. Vertex's parallel Phase 3 de-risks the biology for free. The platform (Compass) is validated by four pharma deals and throws off non-dilutive milestones. MZE782 is a second shot on goal with a rare-disease (PKU) + large-market (CKD) profile. Balance sheet funds into 2029 — no forced raise through the key catalysts. Sell-side raised PoS to 65% and PTs to $50–110, implying 2–4.5× upside from ~$24. If oral APOL1 inhibition is a two-drug market (different cohorts, combinable, payer room for two), Maze is dramatically undervalued at a ~$1.3B cap.

Bear case (2–3 permanent-impairment risks). (1) Vertex wins-most. Inaxaplin reaches accelerated approval ~2027 with big-pharma trial scale, sales force, and a 2-year head start; Maze arrives later into a market Vertex has defined, and a single oral APOL1 inhibitor with first-mover + Breakthrough status captures the bulk of prescriptions — Maze's drug becomes a price-pressured also-ran. (2) The Phase 2 doesn't replicate. N=12 evaluable, open-label, no placebo — the 35.6% broad-AMKD effect could shrink (or fail to separate from placebo) in a controlled pivotal; the −35% data-day drop says the market already half-believes this. (3) Single-asset concentration. MZE829 is the company; MZE782 is unproven (Phase 2 not yet started). A pivotal miss is close to terminal for the equity. Are multiples too high? No — at ~$1.3B vs. ~$528M net cash, the market is already skeptical (EV ~$0.8B for the whole pipeline + platform); the risk isn't over-valuation, it's that the bear scenario is more probable than the sell-side 65% PoS implies.

Pre-mortem (18 months out, thesis broke): It's late 2027. Vertex's AMPLITUDE interim hit and they filed for accelerated approval; Maze's pivotal enrolled slowly (competing for the same genotyped patients Vertex is recruiting) and/or a controlled readout came in softer than the open-label Phase 2; the stock is back near the IPO price, the company is raising again, and the bull thesis ("two-drug market") was wrong — it was winner-take-most, and Maze wasn't the winner.

Contrarian view (what the market refuses to see): The −35% reaction treated "second to Vertex" as near-fatal — but AMKD is a 250k-patient, genetically-stratified, zero-approved-drug market with severe outcomes, exactly the kind of disease where payers and nephrologists will use two mechanisms (and possibly combine an APOL1 inhibitor with SGLT2/standard-of-care). If Maze's dual-mechanism, broad-AMKD (diabetic + hypertensive) positioning holds in a pivotal, "second" can still be a multi-billion-dollar franchise — and the platform/partnered optionality is being valued at roughly zero. The market is pricing a binary (Vertex-wins) that the biology and the unmet need may not honor.

Devil's Advocate (short-seller)

Dismantling the bull case:

• The most dangerous competitor bulls underrate by pretending it's a fair fight: Vertex. Same target, oral once-daily, Breakthrough Therapy, two years ahead in Phase 3, full enrollment H2 2026, accelerated-approval-eligible interim early 2027, and a balance sheet 100× Maze's. Vertex can out-enroll, out-spend, out-market, and — critically — compete for the exact same genotyped patients Maze needs for its pivotal, slowing Maze's trial.
• Revenue concentration = single asset. ~All equity value rides on MZE829. MZE782 is not yet in Phase 2; the partnered programs are royalty lottery tickets controlled by others. There is no diversification cushion against an MZE829 pivotal miss.
• The moat is thinner than "genetics platform" branding implies. The data inputs (MVP/BioVU/All of Us) are not proprietary — Regeneron, AstraZeneca, and Vertex itself mine the same human-genetics cohorts. Compass's edge is methodology, not exclusive data; and the platform's "validation" (four deals) is partly Maze selling programs it couldn't fund alone — a sign of capital constraint as much as platform strength.
• The Phase 2 is statistically thin. 12 evaluable patients, open-label, no placebo control. Proteinuria (uACR) is a surrogate; the real pivotal endpoint will likely be eGFR slope over a long horizon — a higher, slower bar. Open-label proteinuria effects have shrunk in controlled settings before.
• Capital-allocation / incentive flag: the CEO terminated a sell plan and re-adopted one at 4× the share count right before the catalyst — legal, but not the action of someone expecting the stock to compound from here.
• What must hold for today's ~$24 / $1.3B price: that MZE829's effect replicates in a controlled pivotal AND that the AMKD market is big enough and unmet enough to support a clear #2 despite Vertex. If pivotal efficacy disappoints by 20–30% (e.g. broad-AMKD uACR reduction falls toward 20% and doesn't separate cleanly from placebo+SoC), the asset's rNPV collapses and the equity likely halves or worse, since net cash ($528M) becomes the floor and the pipeline-credit evaporates.
• The single scenario that permanently impairs the business: a controlled MZE829 pivotal that fails to show a clinically/statistically convincing proteinuria-or-eGFR benefit — plausibility moderate (the open-label signal is encouraging and the target is validated, but small-N open-label → controlled is exactly where biotech theses die). Secondary kill: Vertex approval + label that makes Maze commercially redundant even with positive data.

Management Questions (ordered by information value)

1. In your planned pivotal AMKD trial, what is the primary endpoint (interim proteinuria/uACR vs. confirmatory eGFR-slope), the control arm, and the target N — and what effect size powers it?
2. How do you enroll a pivotal in the same genotyped APOL1 patients Vertex is recruiting for AMPLITUDE — what is your site/patient-access strategy against a 2-year-ahead, better-resourced competitor?
3. Walk me through why the open-label 35.6% broad-AMKD uACR effect will hold in a placebo-controlled setting — what's your internal estimate of the placebo+SoC proteinuria delta?
4. Is the commercial thesis a two-drug market with Vertex, or winner-take-most? What payer and nephrologist evidence supports room for a clear #2, and where does your dual-mechanism / broad-AMKD (diabetic + hypertensive) positioning win that inaxaplin doesn't?
5. What is the regulatory path and timeline to a registrational filing for MZE829 — is accelerated approval on proteinuria available to you, and what would the confirmatory commitment be?
6. On MZE782, what's the go/no-go from the 2026 Phase 2 starts, and which indication (PKU vs. CKD) carries the value — how big is the CKD opportunity if the SGLT2-like eGFR signal translates?
7. With runway into 2029, what is the next financing trigger — do you intend to fund the MZE829 pivotal to completion without another equity raise, and at what cash threshold do you draw the next Hercules tranche vs. issue equity?
8. How non-exclusive is your access to the human-genetics datasets underpinning Compass, and what stops Vertex/Regeneron/AstraZeneca from replicating your variant-functionalization edge?
9. What are the economics of the partnered book (Shionogi/Neurocrine/Trace) — aggregate remaining milestones and royalty tiers — and how material can non-dilutive cash be over the next 3 years?
10. What is the commercialization plan for MZE829 — build a US nephrology sales force, or partner — and does this team have the experience to execute a first wholly-owned launch?
11. The CEO re-adopted a 4×-larger 10b5-1 sell plan immediately before the HORIZON readout — how should investors read insider selling intent into the pivotal?
12. What is your manufacturing/CMC readiness and CMO concentration for a commercial-scale oral small molecule, and where are the supply single-points?
13. Beyond MZE829 and MZE782, what is the next wholly-owned IND from Compass, and on what timeline — i.e. is the platform still generating internal pipeline or only out-licensed deals?
14. What long-term outcomes data (kidney-failure/ESKD/dialysis delay) will you need to support pricing and payer coverage, and how long until you have it?
15. What is the biggest risk you see to this company over the next 24 months that the Street is currently mis-pricing?

---